Benitec Biopharma Inc. (BNTC) Financial Ratios
13 years of historical data (2013–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
30Y Low11.9·High11.9
P/FCF
N/A
—
5yr avg: N/A
30Y Low8.8·High8.8
P/B Ratio
↑
4.58
↓-55% vs avg
5yr avg: 10.11
30Y Low1.5·High27.9
ROE
↑
-52.5%
↓+84% vs avg
5yr avg: -332.7%
30Y Low-159%·High12%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
BNTC Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Benitec Biopharma Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $323M | $424M | $72M | $6M | $38M | $73M | $32M | $39M | $84M | $65M | $36M |
| Enterprise Value | $226M | $327M | $21M | $4M | $35M | $53M | $23M | $23M | $72M | $52M | $22M |
| P/E Ratio → | -11.71 | — | — | — | — | — | — | 6.71 | — | — | — |
| P/S Ratio | — | — | — | 75.02 | 519.41 | 1237.65 | 333.10 | 4.77 | 409.81 | 331.38 | 139.60 |
| P/B Ratio | 4.58 | 4.35 | 1.52 | 27.85 | 13.16 | 3.65 | 3.16 | 2.32 | 6.08 | 3.93 | 2.57 |
| P/FCF | — | — | — | — | — | — | — | 8.78 | — | — | — |
| P/OCF | — | — | — | — | — | — | — | 8.04 | — | — | — |
P/E links to full P/E history page with 30-year chart
BNTC EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | 49.45 | 474.87 | 906.20 | 236.23 | 2.82 | 352.00 | 263.22 | 86.94 |
| EV / EBITDA | — | — | — | — | — | — | — | 11.90 | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | 12.63 | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | 5.20 | — | — | — |
BNTC Profitability
Margins and return-on-capital ratios measuring operating efficiency
A negative ROE of -52.5% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | 100.0% | 87.7% | -108.5% | 290.7% | 96.2% | -19.3% | 18.3% | 70.0% |
| Operating Margin | — | — | — | -25441.3% | -24457.5% | -23044.1% | -8537.1% | 22.4% | -3143.9% | -6222.9% | -7204.2% |
| Net Profit Margin | — | — | — | -26082.7% | -24942.5% | -23528.8% | -8529.9% | 22.6% | -3079.4% | -1708.7% | -5340.1% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -52.5% | -52.5% | -91.7% | -1268.6% | -159.1% | -91.8% | -61.7% | 12.0% | -41.6% | -21.9% | -85.3% |
| ROA | -50.0% | -50.0% | -76.8% | -374.9% | -133.1% | -83.8% | -53.5% | 10.5% | -38.0% | -20.7% | -80.2% |
| ROIC | — | — | — | — | -31507.1% | -1573.6% | -723.6% | 95.8% | -188.0% | -504.0% | -1358.1% |
| ROCE | -57.6% | -57.6% | -94.2% | -971.8% | -152.3% | -88.8% | -60.9% | 11.9% | -42.3% | -79.6% | -115.0% |
BNTC Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $98M exceeds total debt of $849000, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.01 | 0.01 | 0.01 | 2.77 | 0.28 | 0.01 | 0.04 | — | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -1.00 | -1.07 | -9.50 | -1.13 | -0.98 | -0.92 | -0.95 | -0.86 | -0.81 | -0.97 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | -8.19 | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | -3.58 | — | — | — |
| Interest Coverage | — | — | — | -578.21 | -568.00 | -2312.67 | — | — | — | — | — |
Net cash position: cash ($98M) exceeds total debt ($849000)
BNTC Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Benitec Biopharma Inc.'s current ratio of 54.67x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has improved from 0.94x to 54.67x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 54.67 | 54.67 | 10.49 | 0.94 | 1.90 | 15.05 | 9.51 | 7.10 | 8.20 | 19.70 | 18.73 |
| Quick Ratio | 54.67 | 54.67 | 10.49 | 0.94 | 1.90 | 15.05 | 9.51 | 7.10 | 8.20 | 19.77 | 18.58 |
| Cash Ratio | 54.24 | 54.24 | 10.33 | 0.62 | 1.60 | 14.44 | 8.63 | 6.00 | 6.33 | 15.53 | 17.61 |
| Asset Turnover | — | — | — | 0.02 | 0.01 | 0.00 | 0.01 | 0.42 | 0.01 | 0.01 | 0.02 |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | 0.70 |
| Days Sales Outstanding | — | — | — | 267.67 | 15.00 | 154.66 | 222.01 | 114.64 | 5406.05 | 6308.97 | — |
BNTC Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Benitec Biopharma Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | 14.9% | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | 11.4% | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $36M | $10M | $1M | $2M | $1M | $240280 | $201592 | $165064 | $137596 | $111616 |
Peer Comparison
Compare BNTC with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 BNTCYou | $323M | -11.7 | — | — | — | — | -52.5% | — | — |
 KRYS | $10B | 50.2 | 57.4 | 53.6 | 92.6% | 41.5% | 18.9% | 18.0% | 0.1 |
 RCKT | $378M | -1.7 | — | — | — | — | -60.3% | -62.4% | — |
 QURE | $3B | -12.8 | — | — | 89.5% | -1166.8% | -207.1% | -50.7% | — |
 SLDB | $647M | -4.2 | — | — | — | — | -109.9% | -120.8% | — |
 DTIL | $90M | -1.9 | — | — | 92.0% | -152.2% | -62.7% | -726.2% | — |
 SRPT | $2B | -2.5 | — | — | 59.9% | -29.9% | -53.5% | -31.4% | — |
 ARWR | $12B | -6721.3 | 95.6 | 73.6 | 100.0% | 11.9% | -0.5% | 9.3% | 3.0 |
 NTLA | $2B | -4.1 | — | — | 76.5% | -651.7% | -53.5% | -44.0% | — |
 BEAM | $4B | -43.9 | — | — | 84.0% | -274.6% | -8.1% | -31.1% | — |
 CRSP | $5B | -8.4 | — | — | -6537.0% | -16191.4% | -30.2% | -22.3% | — |
| Healthcare Median | — | 22.1 | 14.2 | 18.4 | 63.9% | -4.4% | -33.2% | -11.7% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 13 years · Updated daily
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare
BNTC — Frequently Asked Questions
Quick answers to the most common questions about buying BNTC stock.
What is Benitec Biopharma Inc.'s P/E ratio?
Benitec Biopharma Inc.'s current P/E ratio is -11.7x. The historical average is 6.7x.
What is Benitec Biopharma Inc.'s ROE?
Benitec Biopharma Inc.'s return on equity (ROE) is -52.5%. The historical average is -57.0%.
Is BNTC stock overvalued?
Based on historical data, Benitec Biopharma Inc. is trading at a P/E of -11.7x. Compare with industry peers and growth rates for a complete picture.